Original Publication Date: >1 December, 2014
Publication / Source: Pain Management
Authors: Brian E Cairns & Parisa Gazerani
In 2010, botulinum neurotoxin A (BoNTA) was approved to prevent headaches in adult patients with chronic migraine. The approval was based on the outcomes of two multicenter clinical trials (PREEMPT 1 & 2) that tested the efficacy and safety of BoNTA [1,2]. In PREEMPT 1, the primary efficacy end point, which was the average number of headache episodes, was similar for BoNTA and placebo. However, the number of headache days was reduced in the BoNTA group .